Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) EPS (Basic) (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of EPS (Basic) readings, the most recent being -$2.64 for Q4 2024.

  • On a quarterly basis, EPS (Basic) fell 1550.0% to -$2.64 in Q4 2024 year-over-year; TTM through Dec 2024 was -$2.91, a 87.74% decrease, with the full-year FY2025 number at -$1.67, up 70.44% from a year prior.
  • EPS (Basic) hit -$2.64 in Q4 2024 for Unicycive Therapeutics, down from -$0.46 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.8 in Q2 2024 to a low of -$2.64 in Q4 2024.
  • Median EPS (Basic) over the past 3 years was -$0.32 (2023), compared with a mean of -$0.47.
  • The widest YoY moves for EPS (Basic): up 375.86% in 2024, down 1550.0% in 2024.
  • Unicycive Therapeutics' EPS (Basic) stood at -$0.35 in 2022, then surged by 54.29% to -$0.16 in 2023, then tumbled by 1550.0% to -$2.64 in 2024.
  • The last three reported values for EPS (Basic) were -$2.64 (Q4 2024), -$0.46 (Q3 2024), and $0.8 (Q2 2024) per Business Quant data.